Phase 3 data presented at the Annual European Congress of Rheumatology (EULAR) 2024 found the biosimilar CT-P47 is similar in terms of efficacy, safety, and immunogenicity profile to the reference product, tocilizumab (RoActemra), for treating patients with moderate-to-severe rheumatoid arthritis (RA).

“The positive topline results from the Phase III study support the biosimilarity of CT-P47 to reference tocilizumab and also provide clinical evidence for the possibility of switching from reference tocilizumab to CT-P47,” said Josef S. Smolen, MD, emeritus professor of medicine at the Medical University of Vienna, Austria, in a press release.

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

https://www.hcplive.com/view/ct-p47-is-promising-biosimilar-candidate-tocilizumab-ra-treatment